Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapyVerónica Rendo, Tobias Sjöblom|Nature Communications|2020Cited by 24
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancerVerónica Rendo, Tobias Sjöblom|Scientific Reports|2020Cited by 7
A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancerVerónica Rendo, Floris Foijer|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 2